Voxeleron
Voxeleron provides AI-powered OCT image analysis software (Orion) and cloud-based clinical trial management (iNebula) to pharmaceutical sponsors, contract research organizations, and reading centers running ophthalmic clinical trials for retinal diseases.
- Company typePrivate
- Founded2010
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Voxeleron does
Voxeleron is a private ophthalmic image analysis software company that develops AI-powered tools for analyzing Optical Coherence Tomography (OCT) retinal images used in clinical trials. Founded in 2010 by Daniel Russakoff and Jonathan Oakley as Voxeleron, LLC, the company serves pharmaceutical and biotech sponsors, contract research organizations (CROs), and reading centers conducting ophthalmic clinical trials for indications including age-related macular degeneration (AMD), diabetic macular edema (DME), glaucoma, and rhegmatogenous retinal detachment (RRD). Its core products are Orion — an advanced OCT analysis software that automatically segments seven retinal layers across multiple OCT device manufacturers including Cirrus and Spectralis — and iNebula, a cloud-based clinical trial management platform launched in May 2022 that enables real-time image data sharing across trial stakeholders.
The company operates an enterprise software licensing and subscription business model, selling directly to trial sponsors and reading centers through a quote-based field sales motion supported by ARVO conference presence, peer-reviewed publications, webinars, and case studies. Disclosed enterprise customers include Ocuphire Pharma, Voiant Clinical, Allgenesis, ONL Therapeutics, and TI Image. Voxeleron holds ISO 13485:2016 (January 2024), SOC 2 Type 1 (March 2023), and FDA 21 CFR Part 11 compliance, positioning it for regulated clinical trial deployments. Funding to date consists of NIH SBIR grants — a Phase I award of $222,991 in February 2017 and a Phase II award of $1.6 million in March 2021 — plus an undisclosed round in March 2024.
In March 2024, the company appointed Joanna Williams (formerly co-founder and COO of ophthalmology CRO Lexitas, with prior leadership at ICON Clinical Research) as CEO. In April 2025, Voiant — a clinical trial imaging solutions provider — acquired Voxeleron to expand its ophthalmic AI capabilities; the company now operates as a Voiant subsidiary under "A Voiant Company" branding. Voxeleron is headquartered in Austin, Texas, and operates with a headcount in the 1–10 range.
Voxeleron firmographics
Firmographics- Name
- Voxeleron
- Legal name
- Voxeleron, LLC
- Website
- https://voxeleron.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Short description
- Voxeleron provides AI-powered OCT image analysis software (Orion) and cloud-based clinical trial management (iNebula) to pharmaceutical sponsors, contract research organizations, and reading centers running ophthalmic clinical trials for retinal diseases.
- Ownership category
- akta.pro rank
Voxeleron industry classification
Industry- Product category
- Ophthalmic Imaging Software
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography) (HLAHAJAB)
- akta.pro secondary industries
- Ocular Imaging & Diagnostic Testing Centers (HLAKAKAN), Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging) (HLAFAKAI)
Keywords
Where Voxeleron is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Voxeleron business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Software Licensing and Subscriptions: The company licenses its Orion OCT analysis software and iNebula cloud platform to pharmaceutical companies, CROs, and reading centers conducting ophthalmic clinical trials. Revenue is generated through software licenses, subscriptions, and potentially usage-based fees for cloud platform access.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Voxeleron product offering
Product offeringCore offering
Voxeleron develops and sells AI-powered ophthalmic image analysis software used by pharmaceutical sponsors, CROs, and reading centers to analyze Optical Coherence Tomography (OCT) images in clinical trials. Its two flagship offerings are Orion, an advanced OCT analysis software that performs automated seven-layer retinal segmentation and fluid quantification across multiple OCT device manufacturers, and iNebula, a cloud-based clinical trial management platform that provides real-time image-data access and stakeholder collaboration for ophthalmic trials.
Product overview
Voxeleron offers a dual-product portfolio: Orion is the core AI-powered advanced OCT analysis software providing device-agnostic automated multi-layer retinal segmentation for clinical research; iNebula is a cloud-based clinical trial management platform that builds on Orion's analysis capabilities to deliver real-time data access and trial workflow optimization. The two products work together to serve pharmaceutical companies, CROs, and research institutions conducting ophthalmic clinical trials.
Differentiator
Problem solved
Functional benefit
Brands
- Orion: Advanced OCT analysis software for ophthalmic image analysis, offering device-independent, multi-layer segmentation of retinal layers.
- iNebula
Products and services
- Orion Advanced AI-powered OCT image analysis software offering automated multi-layer (seven-layer) retinal segmentation, fluid quantification, longitudinal analysis, angiography quantification, and annotation tools. Device-agnostic, processing images across multiple OCT manufacturers. Used by pharmaceutical sponsors, CROs, reading centers, and academic researchers conducting ophthalmic clinical research.
- iNebula Cloud-based clinical trial management platform for ophthalmic research that provides real-time access to image data and insights across multiple stakeholders. Enables sponsors to manage large image datasets, accelerate endpoint evaluation, and share analyses with readers, partners, and investigators.
Quantifiable outcome
- Managed image data from 103 study patients with multiple stakeholders using iNebula platform.
- +2 more outcomes
Companies that use Voxeleron
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
Voxeleron technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature6 records
Voxeleron partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered major, core and minor.
- Voiant ClinicalmajorVoiant, a clinical trial imaging solutions provider, acquired Voxeleron to expand ophthalmic clinical research with AI technology. The integration aims to improve imaging accuracy and accelerate development of treatments for eye diseases.
- Johns Hopkins UniversitycoreInter-institutional agreement with Johns Hopkins University to jointly develop automated methods to count corneal subbasal nerves, based on initial collaboration demonstrating corneal nerve assessment potential for diagnosing and monitoring neuropathies.
- Phoenix Research LabscoreStrategic partnership to apply Voxeleron segmentation technology to Phoenix Research Labs' Image-Guided OCT data for animal eye research. The partnership enabled users to analyze retinal layers and precisely measure changes to thickness and structure over time in preclinical studies.
- European MS Consortium (Sys4MS)minorCollaborative role in the Sys4MS multi-center research initiative aimed at developing new tools for personalized management of MS patients, using Orion for OCT image analysis.
- European Multiple Sclerosis Research GroupsminorCollaboration with neuro-ophthalmology group from University Hospital in Barcelona (Professor Villoslada) and UCSF (Professor Green) to develop OCT segmentation software with clinical utility for MS research.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
Voxeleron competitors and assessment
Company assessmentBroad incumbents
- Topcon Healthcare: Topcon produces the 3D OCT Maestro and Triton series, plus the Harmony image management platform used in ophthalmic clinical trials. It is a broad incumbent offering both OCT hardware and clinical workflow software overlapping with Voxeleron's research-focused solutions.
- Heidelberg Engineering: Heidelberg Engineering manufactures the Spectralis OCT platform, one of the most widely used OCT devices in ophthalmic clinical research. Its HEYEX software and research workflow tools overlap with Voxeleron's device-agnostic analysis positioning, though it is vertically integrated with its own hardware.
- Calyx (formerly Parexel imaging informatics): Calyx offers clinical trial imaging management and review software used by sponsors and CROs to centralize endpoint reads. Its enterprise trial imaging platform is comparable in functional scope to Voxeleron's iNebula, though broader in therapeutic area.
- Carl Zeiss Meditec (ZEISS Medical Technology): ZEISS manufactures the Cirrus OCT platform and offers the Cirrus Advanced Retina Tracking and analysis ecosystem. It is a broad incumbent in retinal imaging for clinical research and practice, and a primary device vendor supported by Voxeleron's device-agnostic Orion software.
- Clario (formerly ERT/Bioclinica imaging): Clario provides clinical trial endpoint technology and imaging core lab services across multiple therapeutic areas, including ophthalmology. It is a broad incumbent in clinical trial imaging and competes for the same pharma-sponsored ophthalmic trial workflow budgets.
- Voiant Clinical: Voiant is a clinical trial imaging CRO that provides centralized reading services and imaging workflow tools, and is now Voxeleron's parent company. As an operator of clinical trial reading centers, Voiant offers competing internal capabilities alongside the integrated Voxeleron AI stack.
Emerging players
- Eyenuk: Eyenuk develops FDA-cleared AI for autonomous detection of diabetic retinopathy and other eye disease screening. It is an emerging player in AI-augmented retinal image analysis with some overlap in retinal biomarker quantification, but its primary focus is screening rather than clinical trial endpoints.
- AEYE Health: AEYE Health builds AI-based retinal screening for diabetic retinopathy and other systemic disease detection from fundus and OCT images. It is an emerging player in AI ophthalmic imaging with some technology overlap, but focused on screening workflows rather than clinical trial OCT analysis.
- Digital Diagnostics (formerly IDx-DR): Digital Diagnostics is a pioneer in autonomous AI diagnostics, with its first FDA-cleared product in diabetic retinopathy. It represents an emerging adjacent player in clinically validated AI for retinal image interpretation, with potential overlap in regulatory and validation expertise.
Direct peers
- Ikerian (formerly RetinAI Medical): Ikerian provides AI-powered ophthalmic image analysis software (Discovery platform) used in clinical research and pharma-sponsored trials for retinal disease. It is the closest direct competitor to Voxeleron's Orion and iNebula products, targeting the same device-agnostic OCT analysis and clinical trial workflow use cases.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Voxeleron social profiles
Digital presenceVoxeleron compliance and trust
Trust signalCompliance4 records
Voxeleron financial estimates
Financial estimateRevenue estimate
Valuation estimate
Voxeleron leadership team
Management profileNumber of profiles
Profiles4 records
Voxeleron funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Voxeleron M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Voxeleron
What does Voxeleron do?
Voxeleron develops and sells AI-powered ophthalmic image analysis software used by pharmaceutical sponsors, CROs, and reading centers to analyze Optical Coherence Tomography (OCT) images in clinical trials. Its two flagship offerings are Orion, an advanced OCT analysis software that performs automated seven-layer retinal segmentation and fluid quantification across multiple OCT device manufacturers, and iNebula, a cloud-based clinical trial management platform that provides real-time image-data access and stakeholder collaboration for ophthalmic trials.
Is Voxeleron a public or private company?
Voxeleron is a private company. It is classified as corporate owned and is currently acquired.
When was Voxeleron founded?
Voxeleron was founded in 2010. It employs 1 to 10 people.
Where is Voxeleron based?
Voxeleron is headquartered in San Francisco, United States, in the North America region.
How does Voxeleron make money?
One revenue line is on record: software Licensing and Subscriptions.
Who are Voxeleron's main competitors?
Broad incumbents on record are Topcon Healthcare, Heidelberg Engineering, Calyx (formerly Parexel imaging informatics), Carl Zeiss Meditec (ZEISS Medical Technology), Clario (formerly ERT/Bioclinica imaging) and Voiant Clinical. Emerging players are Eyenuk, AEYE Health and Digital Diagnostics (formerly IDx-DR). Ikerian (formerly RetinAI Medical) is listed as a direct peer.
Does Voxeleron have an API?
No public API is recorded for Voxeleron.
What industry is Voxeleron in?
Voxeleron's product category is Ophthalmic Imaging Software. Its primary akta.pro industry code is HLAHAJAB, Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography), with a secondary code of HLAKAKAN, Ocular Imaging & Diagnostic Testing Centers. Its NAICS code is 334510 and its SIC code is 3841.